{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:58:17Z","timestamp":1760623097903,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jinf.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T18:52:39Z","timestamp":1555008759000},"page":"15-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases"],"prefix":"10.1016","volume":"79","author":[{"given":"Teresa","family":"Chiacchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Petruccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Vanini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Cuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Scrivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Sauzullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2019.04.010_bib0001","unstructured":"WHO. Global tuberculosis report 2018. www.who.int\/tb\/publications\/global_report\/en\/. 2018."},{"issue":"10","key":"10.1016\/j.jinf.2019.04.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jinf.2019.04.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted Biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jinf.2019.04.010_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"Suppl 2","key":"10.1016\/j.jinf.2019.04.010_bib0006","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0008","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1469-0691.2006.01391.x","article-title":"Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study","volume":"12","author":"Goletti","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.jinf.2019.04.010_bib0009","doi-asserted-by":"crossref","first-page":"e3417","DOI":"10.1371\/journal.pone.0003417","article-title":"Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study","volume":"3","author":"Goletti","year":"2008","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/resp.13272","article-title":"Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease","volume":"23","author":"Goletti","year":"2018","journal-title":"Respirology"},{"issue":"10","key":"10.1016\/j.jinf.2019.04.010_bib0011","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2019.04.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00946-2018","article-title":"An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease","volume":"52","author":"Kik","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0013","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1500803","article-title":"Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype","volume":"195","author":"Riou","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2019.04.010_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2018.04.001","article-title":"Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV\/M. tuberculosis-specific T-cell in co-infected subjects","volume":"198","author":"Chiacchio","year":"2018","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2014.06.009","article-title":"Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients","volume":"69","author":"Chiacchio","year":"2014","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0016","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/13993003.00510-2016","article-title":"First evaluation of QuantiFERON-TB Gold Plus performance in contact screening","volume":"48","author":"Barcellini","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0017","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jinf.2016.09.008","article-title":"First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus","volume":"73","author":"Petruccioli","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2019.04.010_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tube.2017.06.002","article-title":"Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis","volume":"106","author":"Petruccioli","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0019","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","article-title":"Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load","volume":"187","author":"Day","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jinf.2019.04.010_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00430-018-00576-4","article-title":"Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25\/CD134 in response to new antigens of Mycobacterium tuberculosis","volume":"208","author":"Sauzullo","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jinf.2019.04.010_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tube.2018.06.005","article-title":"Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection","volume":"111","author":"Petrone","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01089-2018","article-title":"Can we predict tuberculosis cure? What tools are available?","volume":"52","author":"Goletti","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jinf.2019.04.010_bib0023","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jiac.2017.09.012","article-title":"Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis","volume":"24","author":"Igari","year":"2018","journal-title":"J Infect Chemother"},{"issue":"sup1","key":"10.1016\/j.jinf.2019.04.010_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.jinf.2019.04.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33825-w","article-title":"Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection","volume":"8","author":"Petruccioli","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jinf.2019.04.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26097-x","article-title":"Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases","volume":"8","author":"Sauzullo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2019.04.010_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tube.2017.11.014","article-title":"A multicentre verification study of the QuantiFERON((R))-TB Gold Plus assay","volume":"108","author":"Pieterman","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0028","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1164\/rccm.201704-0817OC","article-title":"Optimization and interpretation of serial QuantiFERON testing to measure acquisition of mycobacterium tuberculosis infection","volume":"196","author":"Nemes","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jinf.2019.04.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01630-2017","article-title":"Proof of concept that most borderline Quantiferon results are true antigen-specific responses","volume":"50","author":"Uzorka","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jinf.2019.04.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00913-2018","article-title":"Tuberculosis after a borderline QuantiFERON result during screening before infliximab","volume":"52","author":"Uzorka","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2019.04.010_bib0031","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tube.2017.07.001","article-title":"Immunological characterization of latent tuberculosis infection in a low endemic country","volume":"106","author":"de Paus","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"issue":"7","key":"10.1016\/j.jinf.2019.04.010_bib0032","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/CVI.00132-07","article-title":"Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation","volume":"14","author":"Leyten","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jinf.2019.04.010_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-9-182","article-title":"New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response","volume":"9","author":"Butera","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2019.04.010_bib0034","first-page":"605","article-title":"Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service","volume":"104","author":"Grzybowsky","year":"1971","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jinf.2019.04.010_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.140099","article-title":"Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches","volume":"91","author":"Goletti","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"6","key":"10.1016\/j.jinf.2019.04.010_bib0036","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.jinf.2019.04.010_bib0037","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319301227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445319301227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:27:35Z","timestamp":1759008455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445319301227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0163445319301227"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2019.04.010","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}